查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1540996

2024-2032 年按疗法、药物类型、最终用户、配销通路和地区分類的多发性骨髓瘤药物市场报告

Multiple Myeloma Drugs Market Report by Therapy, Drug Type, End-User, Distribution Channel, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 138 Pages | 商品交期: 2-3个工作天内

价格

IMARC Group年全球多发性骨髓瘤药物市场规模达223亿美元。

多发性骨髓瘤或卡勒氏症是指一种主要影响浆细胞的血癌。一些最常见的多发性骨髓瘤药物类型包括化疗药物、皮质类固醇和免疫调节药物。这些药物有助于促进骨癒合，预防高血钙、骨折、脊髓受压和贫血，同时最大限度地减少化疗的需要。化疗剂包括各种蒽环类抗生素和烷化剂，例如美法崙、阿霉素、长春新碱和脂质体阿霉素。标靶治疗药物包括蛋白酶体抑制剂，如硼替佐米，以及各种其他化合物，包括地塞米松、泼尼松和沙利度胺。

医疗保健领域的重大发展以及血液癌症盛行率的增加是推动市场成长的关键因素之一。多发性骨髓瘤通常是由特定的基因异常引起的，这种疾病的治疗涉及调节免疫系统的药物，并有助于提高化疗、放疗、干细胞移植和血小板输注的效率。此外，消费者对生物治疗药物益处的认识不断提高，生物治疗药物利用人体的免疫系统来识别和攻击骨髓瘤细胞，也推动了市场的成长。此外，各种技术进步，例如用于治疗多发性骨髓瘤的 microRNA 疗法和奈米药物的开发，正在成为另一个生长诱导因素。这些药物用于促进大分子药物输送到骨髓并催化抗肿瘤反应。其他因素，包括医疗保健支出的增加以及医学领域广泛的研发（R&D）活动，预计将进一步推动市场发展。

本报告回答的关键问题：

  • 迄今为止，全球多发性骨髓瘤药物市场表现如何，未来几年将如何表现？
  • 主要区域市场有哪些？
  • COVID-19 对全球多发性骨髓瘤药物市场有何影响？
  • 基于该疗法的市场区隔是什么？
  • 根据药物类型分類的市场是怎么样的？
  • 基于最终用户的市场区隔是什么？
  • 基于配销通路的市场区隔是什么？
  • 产业价值链的各个阶段是什么？
  • 该行业的关键驱动因素和挑战是什么？
  • 全球多发性骨髓瘤药物市场的结构如何？
  • 产业竞争程度如何？

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 数据来源
    • 主要来源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：管道评估/临床试验产品/临床开发

  • PegIntron（聚乙二醇化干扰素 alfa-2b）
  • 泊马度胺
  • 坦斯匹霉素 (KOS-953)
  • MLN 9708
  • SRT-501-012
  • BHQ880
  • 帕比司他
  • ZIO-101
  • VEGF-Trap（阿柏西普）
  • 狄诺塞麦
  • 哌立福辛
  • Actimid (CC-5013)
  • 罗米地辛
  • 普利地辛（Aplidin）
  • 坦西罗莫司（Torisel）
  • 索拉非尼
  • 贝伐珠单抗

第 6 章：全球多发性骨髓瘤药物市场

  • 市场概况
  • 市场表现
  • COVID-19 的影响
  • 市场预测

第 7 章：市场区隔：透过治疗

  • 标靶治疗
    • 市场趋势
    • 市场预测
  • 生物疗法
    • 市场趋势
    • 市场预测
  • 化疗
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 8 章：市场区隔：依药物类型

  • 免疫调节药物
    • 市场趋势
    • 市场预测
  • 蛋白酶体抑制剂
    • 市场趋势
    • 市场预测
  • 组蛋白去乙酰化酶抑制剂
    • 市场趋势
    • 市场预测
  • 单株抗体药物
    • 市场趋势
    • 市场预测
  • 类固醇
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 9 章：市场区隔：按最终用户

  • 男士
    • 市场趋势
    • 市场预测
  • 女性
    • 市场趋势
    • 市场预测

第 10 章：市场区隔：按配销通路

  • 医院药房
    • 市场趋势
    • 市场预测
  • 零售药局
    • 市场趋势
    • 市场预测
  • 网路药局
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 11 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场趋势
    • 市场细分：按国家/地区
    • 市场预测

第 12 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 13 章：价值链分析

第 14 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 15 章：价格指标

第16章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Amgen Inc.
    • Bristol Myers Squibb
    • Daiichi Sankyo Co.
    • Sanofi-Aventis Groupe (Genzyme Corporation)
    • Johnson & Johnson Services, Inc.
    • Merck & Co., Inc.
    • Novartis International AG
    • Pfizer Inc.
    • PHARMA MAR, SA
    • Takeda Pharmaceutical Company Limited.
    • Teva Pharmaceutical Industries Ltd.
Product Code: SR112024A2169

The global multiple myeloma drugs market size reached US$ 22.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 35.5 Billion by 2032, exhibiting a growth rate (CAGR) of 5.2% during 2024-2032.

Multiple myeloma, or Kahler's disease, refers to a form of blood cancer that primarily affects the plasma cells. Some of the most common types of multiple myeloma drugs include chemotherapeutic agents, corticosteroids and immunomodulatory agents. These pharmaceutical drugs aid in promoting bone healing, prevent hypercalcemia, bone fracture, spinal cord compression and anemia, while minimizing the need for chemotherapy. The chemotherapeutic agents include various anthracycline antibiotics and alkylating agents, such as melphalan, doxorubicin, vincristine and liposomal doxorubicin. The targeted therapy drugs include proteasome inhibitor, such as bortezomib, and various other compounds, including dexamethasone, prednisone and thalidomide.

Significant developments in the healthcare sector, along with the increasing prevalence of hematological cancer, is one of the key factors driving the growth of the market. Multiple myeloma is usually caused by specific genetic abnormalities, and the treatment of this disease involves drugs that modulate the immune system and aid in enhancing the efficiency of chemotherapies, radiation therapies, stem cell transplants and platelet transfusion. Furthermore, rising consumer awareness regarding the benefits of biologic therapy drugs, which utilize the body's immune system to identify and attack the myeloma cells, is also providing a boost to the market growth. Additionally, various technological advancements, such as the development of microRNA therapeutics and nanomedicines for the treatment of multiple myeloma, is acting as another growth-inducing factor. These medicines are used to facilitate the delivery of macromolecular agents into the bone marrow and catalyze antitumor responses. Other factors, including the rising healthcare expenditures and extensive research and development (R&D) activities in the field of medical sciences, are projected to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global multiple myeloma drugs market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on therapy, drug type, end-user and distribution channel.

Breakup by Therapy:

Targeted Therapy

Biologic Therapy

Chemotherapy

Others

Breakup by Drug Type:

Immunomodulatory Drugs

Proteasome Inhibitors

Histone Deacetylase Inhibitors

Monoclonal Antibody Drugs

Steroids

Others

Breakup by End-User:

Men

Women

Breakup by Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Others

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Amgen Inc., Bristol Myers Squibb, Daiichi Sankyo Co., Ltd., Sanofi-Aventis Groupe (Genzyme Corporation), Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis International AG, Pfizer Inc., PHARMA MAR, S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., etc.

Key Questions Answered in This Report:

  • How has the global multiple myeloma drugs market performed so far and how will it perform in the coming years?
  • What are the key regional markets?
  • What has been the impact of COVID-19 on the global multiple myeloma drugs market?
  • What is the breakup of the market based on the therapy?
  • What is the breakup of the market based on the drug type?
  • What is the breakup of the market based on the end-user?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global multiple myeloma drugs market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Pipeline Assesment/Clinical Trial Products/Clinical Developments

  • 5.1 PegIntron (Pegylated interferon alfa-2b)
  • 5.2 Pomalidomide
  • 5.3 Tanespimycin (KOS-953)
  • 5.4 MLN 9708
  • 5.5 SRT-501- 012
  • 5.6 BHQ880
  • 5.7 Panobinostat
  • 5.8 ZIO-101
  • 5.9 VEGF-Trap(Aflibercept)
  • 5.10 Denosumab
  • 5.11 Perifosine
  • 5.12 Actimid (CC-5013)
  • 5.13 Romidepsin
  • 5.14 Plitidepsin (Aplidin)
  • 5.15 Temsirolimus (Torisel)
  • 5.16 Sorafenib
  • 5.17 Bevacizumab

6 Global Multiple Myeloma Drugs Market

  • 6.1 Market Overview
  • 6.2 Market Performance
  • 6.3 Impact of COVID-19
  • 6.4 Market Forecast

7 Market Breakup by Therapy

  • 7.1 Targeted Therapy
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Biologic Therapy
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Chemotherapy
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Drug Type

  • 8.1 Immunomodulatory Drugs
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Proteasome Inhibitors
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Histone Deacetylase Inhibitors
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Monoclonal Antibody Drugs
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Steroids
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Others
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast

9 Market Breakup by End-User

  • 9.1 Men
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Women
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast

10 Market Breakup by Distribution Channel

  • 10.1 Hospital Pharmacies
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Retail Pharmacies
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Online Pharmacies
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast
  • 10.4 Others
    • 10.4.1 Market Trends
    • 10.4.2 Market Forecast

11 Market Breakup by Region

  • 11.1 North America
    • 11.1.1 United States
      • 11.1.1.1 Market Trends
      • 11.1.1.2 Market Forecast
    • 11.1.2 Canada
      • 11.1.2.1 Market Trends
      • 11.1.2.2 Market Forecast
  • 11.2 Asia Pacific
    • 11.2.1 China
      • 11.2.1.1 Market Trends
      • 11.2.1.2 Market Forecast
    • 11.2.2 Japan
      • 11.2.2.1 Market Trends
      • 11.2.2.2 Market Forecast
    • 11.2.3 India
      • 11.2.3.1 Market Trends
      • 11.2.3.2 Market Forecast
    • 11.2.4 South Korea
      • 11.2.4.1 Market Trends
      • 11.2.4.2 Market Forecast
    • 11.2.5 Australia
      • 11.2.5.1 Market Trends
      • 11.2.5.2 Market Forecast
    • 11.2.6 Indonesia
      • 11.2.6.1 Market Trends
      • 11.2.6.2 Market Forecast
    • 11.2.7 Others
      • 11.2.7.1 Market Trends
      • 11.2.7.2 Market Forecast
  • 11.3 Europe
    • 11.3.1 Germany
      • 11.3.1.1 Market Trends
      • 11.3.1.2 Market Forecast
    • 11.3.2 France
      • 11.3.2.1 Market Trends
      • 11.3.2.2 Market Forecast
    • 11.3.3 United Kingdom
      • 11.3.3.1 Market Trends
      • 11.3.3.2 Market Forecast
    • 11.3.4 Italy
      • 11.3.4.1 Market Trends
      • 11.3.4.2 Market Forecast
    • 11.3.5 Spain
      • 11.3.5.1 Market Trends
      • 11.3.5.2 Market Forecast
    • 11.3.6 Russia
      • 11.3.6.1 Market Trends
      • 11.3.6.2 Market Forecast
    • 11.3.7 Others
      • 11.3.7.1 Market Trends
      • 11.3.7.2 Market Forecast
  • 11.4 Latin America
    • 11.4.1 Brazil
      • 11.4.1.1 Market Trends
      • 11.4.1.2 Market Forecast
    • 11.4.2 Mexico
      • 11.4.2.1 Market Trends
      • 11.4.2.2 Market Forecast
    • 11.4.3 Others
      • 11.4.3.1 Market Trends
      • 11.4.3.2 Market Forecast
  • 11.5 Middle East and Africa
    • 11.5.1 Market Trends
    • 11.5.2 Market Breakup by Country
    • 11.5.3 Market Forecast

12 SWOT Analysis

  • 12.1 Overview
  • 12.2 Strengths
  • 12.3 Weaknesses
  • 12.4 Opportunities
  • 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

  • 14.1 Overview
  • 14.2 Bargaining Power of Buyers
  • 14.3 Bargaining Power of Suppliers
  • 14.4 Degree of Competition
  • 14.5 Threat of New Entrants
  • 14.6 Threat of Substitutes

15 Price Indicators

16 Competitive Landscape

  • 16.1 Market Structure
  • 16.2 Key Players
  • 16.3 Profiles of Key Players
    • 16.3.1 Amgen Inc.
      • 16.3.1.1 Company Overview
      • 16.3.1.2 Product Portfolio
      • 16.3.1.3 Financials
      • 16.3.1.4 SWOT Analysis
    • 16.3.2 Bristol Myers Squibb
      • 16.3.2.1 Company Overview
      • 16.3.2.2 Product Portfolio
      • 16.3.2.3 Financials
      • 16.3.2.4 SWOT Analysis
    • 16.3.3 Daiichi Sankyo Co.
      • 16.3.3.1 Company Overview
      • 16.3.3.2 Product Portfolio
      • 16.3.3.3 Financials
      • 16.3.3.4 SWOT Analysis
    • 16.3.4 Sanofi-Aventis Groupe (Genzyme Corporation)
      • 16.3.4.1 Company Overview
      • 16.3.4.2 Product Portfolio
      • 16.3.4.3 SWOT Analysis
    • 16.3.5 Johnson & Johnson Services, Inc.
      • 16.3.5.1 Company Overview
      • 16.3.5.2 Product Portfolio
      • 16.3.5.3 Financials
      • 16.3.5.4 SWOT Analysis
    • 16.3.6 Merck & Co., Inc.
      • 16.3.6.1 Company Overview
      • 16.3.6.2 Product Portfolio
      • 16.3.6.3 Financials
      • 16.3.6.4 SWOT Analysis
    • 16.3.7 Novartis International AG
      • 16.3.7.1 Company Overview
      • 16.3.7.2 Product Portfolio
      • 16.3.7.3 Financials
      • 16.3.7.4 SWOT Analysis
    • 16.3.8 Pfizer Inc.
      • 16.3.8.1 Company Overview
      • 16.3.8.2 Product Portfolio
      • 16.3.8.3 Financials
      • 16.3.8.4 SWOT Analysis
    • 16.3.9 PHARMA MAR, S.A.
      • 16.3.9.1 Company Overview
      • 16.3.9.2 Product Portfolio
      • 16.3.9.3 Financials
    • 16.3.10 Takeda Pharmaceutical Company Limited.
      • 16.3.10.1 Company Overview
      • 16.3.10.2 Product Portfolio
      • 16.3.10.3 Financials
      • 16.3.10.4 SWOT Analysis
    • 16.3.11 Teva Pharmaceutical Industries Ltd.
      • 16.3.11.1 Company Overview
      • 16.3.11.2 Product Portfolio
      • 16.3.11.3 Financials
      • 16.3.11.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Multiple Myeloma Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Multiple Myeloma Drugs Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Multiple Myeloma Drugs Market: Breakup by Therapy (in %), 2023
  • Figure 4: Global: Multiple Myeloma Drugs Market: Breakup by Drug Type (in %), 2023
  • Figure 5: Global: Multiple Myeloma Drugs Market: Breakup by End-User (in %), 2023
  • Figure 6: Global: Multiple Myeloma Drugs Market: Breakup by Distribution Channel (in %), 2023
  • Figure 7: Global: Multiple Myeloma Drugs Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Multiple Myeloma Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 9: Global: Multiple Myeloma Drugs (Targeted Therapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Multiple Myeloma Drugs (Targeted Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Multiple Myeloma Drugs (Biologic Therapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Multiple Myeloma Drugs (Biologic Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Multiple Myeloma Drugs (Chemotherapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Multiple Myeloma Drugs (Chemotherapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Multiple Myeloma Drugs (Others) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Multiple Myeloma Drugs (Others) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Multiple Myeloma Drugs (Immunomodulatory Drugs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Multiple Myeloma Drugs (Immunomodulatory Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Multiple Myeloma Drugs (Proteasome Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Multiple Myeloma Drugs (Proteasome Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Multiple Myeloma Drugs (Histone Deacetylase Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Multiple Myeloma Drugs (Histone Deacetylase Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Multiple Myeloma Drugs (Monoclonal Antibody Drugs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Multiple Myeloma Drugs (Monoclonal Antibody Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Multiple Myeloma Drugs (Steroids) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Multiple Myeloma Drugs (Steroids) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Multiple Myeloma Drugs (Others) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Multiple Myeloma Drugs (Others) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: Multiple Myeloma Drugs (Men) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Multiple Myeloma Drugs (Men) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Global: Multiple Myeloma Drugs (Women) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Global: Multiple Myeloma Drugs (Women) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Global: Multiple Myeloma Drugs (Hospital Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Global: Multiple Myeloma Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Global: Multiple Myeloma Drugs (Retail Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Global: Multiple Myeloma Drugs (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: Global: Multiple Myeloma Drugs (Online Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: Global: Multiple Myeloma Drugs (Online Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: Global: Multiple Myeloma Drugs (Others) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: Global: Multiple Myeloma Drugs (Others) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: North America: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: North America: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: United States: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: United States: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: Canada: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: Canada: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Asia Pacific: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Asia Pacific: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: China: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: China: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: Japan: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: Japan: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: India: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: India: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: South Korea: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: South Korea: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: Australia: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: Australia: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Indonesia: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Indonesia: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Others: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Others: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Europe: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Europe: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Germany: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Germany: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: France: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: France: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: United Kingdom: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: United Kingdom: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Italy: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Italy: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Spain: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: Spain: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Russia: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: Russia: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Others: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 78: Others: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Latin America: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 80: Latin America: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Brazil: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 82: Brazil: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 83: Mexico: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 84: Mexico: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 85: Others: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 86: Others: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 87: Middle East and Africa: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 88: Middle East and Africa: Multiple Myeloma Drugs Market: Breakup by Country (in %), 2023
  • Figure 89: Middle East and Africa: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 90: Global: Multiple Myeloma Drugs Industry: SWOT Analysis
  • Figure 91: Global: Multiple Myeloma Drugs Industry: Value Chain Analysis
  • Figure 92: Global: Multiple Myeloma Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Multiple Myeloma Drugs Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Multiple Myeloma Drugs Market Forecast: Breakup by Therapy (in Million US$), 2024-2032
  • Table 3: Global: Multiple Myeloma Drugs Market Forecast: Breakup by Drug Type (in Million US$), 2024-2032
  • Table 4: Global: Multiple Myeloma Drugs Market Forecast: Breakup by End-User (in Million US$), 2024-2032
  • Table 5: Global: Multiple Myeloma Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 6: Global: Multiple Myeloma Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 7: Global: Multiple Myeloma Drugs Market Structure
  • Table 8: Global: Multiple Myeloma Drugs Market: Key Players